GlassScriptPhysician profile
Nancy S Giaimo
NPI 1699719971
$3,031.82
in general payments reported to CMS, 2019-2025
34 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $449 · 2022: $582 · 2023: $921 · 2024: $777 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,000.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $707.26 | 2021-2025 | |
| Novo Nordisk INC | $386.44 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $248.29 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Amgen INC. | $164.70 | 2021-2024 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $143.26 | 2021-2024 | Farxiga, Breztri |
| Pfizer INC. | $127.20 | 2023-2025 | |
| Abbott Laboratories | $112.90 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Lilly USA, LLC | $106.17 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Sumitomo Pharma America, INC. | $99.78 | 2023-2025 | Gemtesa |
| Exact Sciences Corporation | $92.55 | 2023-2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $83.08 | 2021 | |
| Medtronic, INC. | $82.93 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.38 | 2023-2024 | Jardiance |
| Corium, LLC | $53.56 | 2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $52.00 | 2022-2024 | Rexulti |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $45.56 | 2021-2025 | Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $42.11 | 2021-2023 | |
| Ironshore Pharmaceuticals INC. | $41.48 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $35.92 | 2022 | |
| Phadia US INC. | $35.09 | 2024 | Immunocap |
| Takeda Pharmaceuticals U.S.A., INC. | $33.23 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $32.14 | 2021-2024 | Eliquis |
| Almatica Pharma LLC | $27.30 | 2022 | |
| Esperion Therapeutics, INC. | $27.21 | 2024 | Nexletol |
| Eisai INC. | $25.60 | 2021 | |
| Astellas Pharma US INC | $24.28 | 2021 | |
| Noven Therapeutics, LLC | $18.31 | 2024 | Xelstrym |
| Collegium Pharmaceutical, INC. | $17.68 | 2025 | Jornay Pm |
| Inspire Medical Systems, INC. | $17.37 | 2024 | Inspire |
| Acerus Pharmaceuticals Corporation | $17.17 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.08 | 2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $14.85 | 2021 | |
| Daiichi Sankyo INC. | $14.75 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.19 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Giaimo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.